The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, May 20, 2025, 12:00 Hrs [IST] GSK plc announced ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM).

Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly ...

In DREAMM-8, at a median follow-up of 21.8 months, the median PFS was not yet reached with the Blenrep combination compared to 12.7 months in the bortezomib combination.

GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or ...